Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions].

Gan to kagaku ryoho. Cancer & chemotherapy - 1 Jul 2026

Nakamichi Shinji, Kubota Kaoru

Abstract excerpt

KRAS G12C has emerged as a clinically important therapeutic target in non-small cell lung cancer (NSCLC), representing a major advance in the treatment of KRAS-driven malignancies. The development of covalent inhibitors targeting the switch-Ⅱ pocket of inactive, GDP-bound KRAS has transformed a previously undruggable oncogene into a molecularly actionable target. First-generation KRAS G12C inhibitors, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to SOS1 gene

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Mutation

Share to Oncogene Protein p21(ras)

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 42551924

Genes

KRAS
SOS1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions].PMID 42551924Read ↗

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Semantic proximity Read ↗

From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC.Semantic proximity Read ↗

KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.Semantic proximity Read ↗

The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?Semantic proximity Read ↗

Targeting KRAS G12C in non-small cell lung cancer: Breakthrough inhibitors and combination approaches.Semantic proximity Read ↗

Targeting KRAS in cancer.Semantic proximity Read ↗

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.Semantic proximity Read ↗

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.Semantic proximity Read ↗

Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies.Semantic proximity Read ↗

Recent advances in therapeutic targeting of the KRAS pathway in cancer.Semantic proximity Read ↗

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic StrategiesSemantic proximity Read ↗

Resistance looms for KRAS G12C inhibitors and rational tackling strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.